Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Beltran-Bless, AA; Clemons, MJ; Fesl, C; Greil, R; Pond, GR; Balic, M; Vandermeer, L; Bjelic-Radisic, V; Singer, CF; Steger, GG; Helfgott, R; Egle, D; Sölkner, L; Gampenrieder, SP; Kacerovsky-Strobl, S; Suppan, C; Ritter, M; Rinnerthaler, G; Pfeiler, G; Fohler, H; Hlauschek, D; Hilton, J; Gnant, M.
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
Eur J Cancer. 2023; 180:108-116
Doi: 10.1016/j.ejca.2022.12.003
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Balic Marija
- Bjelic-Radisic Vesna
- Rinnerthaler Gabriel
- Suppan Christoph
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast Cancer Trialist Group (EBCTCG) meta-analysis. Despite multiple regimens evaluated, there was no signal of varying efficacy with type, dose/dose intensity of bisphosphonate administration. We evaluated the effect of early treatment cessation using long-term outcome data from the ABCSG-12 trial. PATIENTS AND METHODS: ABCSG-12 randomized 1803 hormone-receptor positive EBC patients on ovarian suppression between 1999 and 2006 to receive 4 mg zoledronic acid 6-monthly or not (and tamoxifen or anastrozole, 2:2 factorial design). In the current study, we evaluated whether the number of zoledronate infusions had an impact on breast cancer-specific outcomes. We hypothesized that amongst patients who received at least one zoledronate infusion, the number of infusions had no effect on outcomes. Time-to-event endpoints were analysed with Cox models and Kaplan Meier curves starting from a 3-year landmark. BMD analysis was restricted to patients who participated in the BMD sub-study. RESULTS: 725 patients who received at least one zoledronate infusion were included in the time-to-event analysis. There was no statistically significant difference in disease-free or overall survival in the patients who received ≤6 zoledronate infusions (n = 170) compared to those who received ≥7 zoledronate infusions (n = 555). CONCLUSIONS: Comparable to efforts to de-escalate treatment duration in metastatic bone disease, there was no evidence to indicate that a reduced number of zoledronate infusions is associated with reduced adjuvant efficacy. Further studies to define optimal regimens of adjuvant bone-targeted therapies are required.
- Find related publications in this database (using NLM MeSH Indexing)
- Female - administration & dosage
- Humans - administration & dosage
- Adjuvants, Immunologic - therapeutic use
- Breast Neoplasms - pathology
- Chemotherapy, Adjuvant - administration & dosage
- Diphosphonates - administration & dosage
- Treatment Outcome - administration & dosage
- Zoledronic Acid - therapeutic use
- Find related publications in this database (Keywords)
- Breast cancer
- Adjuvant bisphosphonate
- Duration
- Zoledronate